Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. - Wikidata - wikimedia - TriplyDB

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

http://www.wikidata.org/entity/Q33783119

about

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastases A new era for the systemic therapy of neuroendocrine tumors.Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver.The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.New therapeutic options for metastatic malignant insulinomas.Role of everolimus in pancreatic neuroendocrine tumors.Sunitinib for advanced pancreatic neuroendocrine tumors.Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.Sunitinib in pancreatic neuroendocrine tumors.Everolimus for the treatment of pancreatic neuroendocrine tumors.Streptozocin-based chemotherapy is not history in neuroendocrine tumours.Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism.Pancreatic neuroendocrine tumors: a review.Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view.Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.The use of biomarkers in neuroendocrine tumours.Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.The treatment of hyperinsulinemic hypoglycaemia in adults: an update.A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome.The safety of available treatments options for neuroendocrine tumors.Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors.

P2860

Q26768483-0975A97E-512A-4736-AD5B-6DBF1DA154AF Q26996521-CF69A01D-88C5-456D-9A9B-945D439F4D02 Q28551275-650A30D5-3E31-4594-91CF-DC6FE1B65EBA Q34248487-D9E8F426-A10C-4058-9117-224791D20566 Q34301030-FB499077-439D-4289-9672-532BA102E112 Q34452319-F09B3D78-8CF2-45B8-930C-04001DFCE0EE Q34688938-CC33D5D4-2F97-4425-8A1F-7FF78A385CAE Q35097493-8A5847D8-7244-4B66-9CE9-BB05869FF659 Q35760798-4A96528A-17E9-48A0-B073-9DC53B6CC6D2 Q35810562-6620C7EB-F140-4D6A-9C30-6489541CD82F Q35863865-46387341-2958-44E5-886D-73C7843F20C8 Q36012272-07B15B4A-31EC-41DD-851E-8DEE6C5A03CA Q36885671-9C90E9BC-F858-4067-897F-7F5892A4A750 Q37017037-B0F99487-2E6A-4C91-8353-E02DB1F9D9A1 Q37350299-A33E1042-CBA0-4933-B0AE-F911FC2DE32A Q37354131-F45FE60B-93A9-4E31-9622-709B3DB86C50 Q37702716-6D37C96F-2053-4060-A9F7-4725F2236E71 Q37886036-4CBA358E-E93B-4912-895B-B4B2D1E81124 Q37935772-0E3BE925-31AA-4896-9546-14A607C0792F Q37960905-4E47A11C-D6B6-4AD9-9201-C5650B568938 Q38014495-ED1CD997-0200-4719-BAF0-AAA181FBBD58 Q38015764-16FD34A7-450F-4C0E-AA1C-69A9405DD10C Q38032923-31FA2769-D285-41C8-B66E-FC11BA6AD866 Q38035223-58D25E84-7597-4600-A2DC-92A2D8A0F06A Q38066186-8D785437-6E33-4B0D-B3CF-6D66859380AF Q38096476-0FB8584F-B261-40CE-A939-EC1ADDFBBE14 Q38368300-6C00316B-08B4-462B-ACDC-E3D71EEEA6E8 Q38372459-D0C08423-C8AF-4CB6-92AE-39F05C70DA4D Q38412071-796BCCCA-9F23-44A2-A55B-520F90F84603 Q38458505-04A39853-5EAB-4D63-B1DB-2FB6986C3C36 Q38557054-C317617E-4C56-48E8-ACF1-2050202C4A9C Q38609117-EBD03F37-240F-4797-BEBF-C54B721CE91E Q38650864-5F6C6EB4-FBB2-4B21-AD95-81A90409050B Q38711101-524D5964-37D4-4117-BF8B-8DDE650F2B93 Q38842250-5BED8EA7-809F-411D-A462-A0163BCC9BF2 Q38909078-CA813C90-6726-46C2-8D8B-0C827824A502 Q38953515-11BB00BB-7DFC-491E-891F-9CAF9AFB8DAC Q38958626-1C20AAB0-BCFF-42B6-B473-BF8978547E86 Q39433254-1615E6C3-3C53-4A36-97ED-0E079224E201 Q39773838-00FE6293-AF0F-4096-A774-9CD13BAC2A87

P2860

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

http://www.wikidata.org/entity/Q33783119

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@ast

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@en

type

label

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@ast

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@en

prefLabel

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@ast

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@en

P1433

Q33783119-7D19BDF4-DB07-4D5A-AD56-4977122CCDF1

P1476

Q33783119-93D5E80E-6FDD-4552-9D78-AF564F936A35

P2093

Q33783119-254619C0-9C3F-4377-8F5B-552E29BC2406

Q33783119-3343DDDC-7D28-4AC2-AA93-5137F4D669C5

Q33783119-489AF3F0-F4F2-4807-9138-417A9C6540DD

Q33783119-4C7372F9-53D9-4043-B3BC-44D417699AB8

Q33783119-5191F803-B5EC-4EF4-B9A6-C668835217AF

Q33783119-6E9FCDBE-8BD4-4E8E-9B34-75B4DD431FFF

Q33783119-9298AAE4-B0E2-476B-861F-CD69CDEA07EA

Q33783119-9C04C126-C724-4CDB-86A9-7271AD54019A

Q33783119-9CB3F928-E798-4487-B1E2-886C5ACCB547

Q33783119-C230A05E-598F-4196-9323-27D2CAE82C61

P2860

Q33783119-201C0D08-BC45-4332-BDBD-185E579AF1FE

Q33783119-423D8F31-1DC6-4DFE-B117-1DC91B5B8DA0

Q33783119-5A904679-6F95-411D-B6C8-C472388CF385

Q33783119-61604DAD-2B77-4430-9AC7-E9A2070290C4

Q33783119-61E3F8CD-26D3-4378-AC03-7EDF872C04AE

Q33783119-656A316D-7731-4F10-8972-8D33C75D912A

Q33783119-82DC13FE-BA69-49DE-B998-593D78560722

Q33783119-8F4C7858-C65B-442F-91DC-369785194DF5

Q33783119-9404B720-F149-4015-8300-B74A93F67B59

Q33783119-9706A6BD-E672-4945-8CC1-108F1FD8DCDF

P2888

Q33783119-E3F4A5D1-84F1-4C4E-B04B-5FDE484681B0

P304

Q33783119-1BA48A3C-BB50-4556-9682-5FB5A0718902

P31

Q33783119-1E6C7B08-5C9C-4210-8F54-04F172F8C09C

P356

Q33783119-885708E7-471A-40F1-93E8-F77EB4EF440D

P407

Q33783119-E9A9475B-88A1-4A83-BBFA-06A222EB4F46

P433

Q33783119-7B49958F-EF56-4D7D-9677-D538B3D0D7DC

P478

Q33783119-AB8CBCC5-6B0E-4B9B-BC38-F2B078D1839B

P577

Q33783119-E2AFE8A6-35E0-44C5-97FC-F87C07FCB5C1

P5875

Q33783119-918DAA3D-42E9-4AE5-96D9-B043F35A98DE

P6179

Q33783119-F89383B8-A104-47AD-9D51-968600772900

P698

Q33783119-FE56B711-D5FD-43BA-87E9-0C8338C56FBE

P921

Q33783119-EF7AAEEC-A297-4415-8A2A-B920B2D17CCF

P932

Q33783119-2AE226D7-1792-42F8-B984-E8B2286D431D

P356

P1433

British Journal of Cancer

P1476

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

@en

P2093

A Hackshaw

http://www.w3.org/2001/XMLSchema#string

A Kirkwood

http://www.w3.org/2001/XMLSchema#string

A Mayer

http://www.w3.org/2001/XMLSchema#string

A Papadopoulou

http://www.w3.org/2001/XMLSchema#string

C Toumpanakis

http://www.w3.org/2001/XMLSchema#string

D Hochhauser

http://www.w3.org/2001/XMLSchema#string

D Sarker

http://www.w3.org/2001/XMLSchema#string

F Grillo

http://www.w3.org/2001/XMLSchema#string

I Kayani

http://www.w3.org/2001/XMLSchema#string

J Bell

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients.

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours.

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

P2888

P304

1106-1112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605618

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42109426

http://www.w3.org/2001/XMLSchema#string

P6179

1005779365

http://www.w3.org/2001/XMLSchema#string

P698

20234360

http://www.w3.org/2001/XMLSchema#string

P921

P932

2853102

http://www.w3.org/2001/XMLSchema#string